News SinoMab BioScience Limited

Equities

3681

HK0000544194

Market Closed - Hong Kong S.E. Other stock markets 04:08:16 2024-04-24 am EDT			5-day change	1st Jan Change
1.9 ^HKD	0.00%		+0.53%	+13.10%

Mar. 25	SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 07	SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy	Apr. 16	AQ
SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	Feb. 07	CI
SinoMab BioScience Raises HK$62.2 Million from Thirteen Share Subscriptions	Jan. 15	MT
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors	Dec. 15	MT
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China	Nov. 28	MT
SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China	Nov. 27	CI
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%	Nov. 15	MT
Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE	Nov. 15	CI
China Accepts New Drug Application of SinoMab's Dermatitis Medication; Shares Rise 3%	23-09-11	MT
SinoMab's IND Application of SM17 has once again Received Approval from NAMP	23-09-11	AQ
Sinomab Bioscience Limited announces Change of Non-Executive Directors	23-09-06	CI
Chinese Regulator Accepts License Application for SinoMab's Arthritis Drug	23-09-05	MT
China Accepts SinoMab's Biologics License Application for Arthritis Treatment	23-09-05	MT
SinoMab BioScience Limited Announces National Medical Products Administration Accepts Biologics License Application for SM03 in the Treatment of Rheumatoid Arthritis	23-09-05	CI
SinoMab Bioscience to Shrink Loss in H1	23-08-22	MT
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
SinoMab Bioscience Obtains Clinical Trial Approval in China for Asthma Drug	23-08-15	MT
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP	23-08-14	AQ
Sinomab Bioscience Limited Announces IND Approval for Sm17 by Nmpa	23-08-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News SinoMab BioScience Limited

Equities

3681

HK0000544194

Summary

Filters